What are the recommended treatment options for a patient with high LDL cholesterol who cannot use statins or PCSK9 inhibitors (e.g., Repatha)?

Treatment Options for High Cholesterol When Statins and PCSK9 Inhibitors Cannot Be Used

For patients who cannot tolerate statins or PCSK9 inhibitors like Repatha, start with ezetimibe 10 mg daily as first-line therapy, which can reduce LDL-C by approximately 15-20%. 1

Algorithmic Treatment Approach

Step 1: Optimize Lifestyle and Rule Out Secondary Causes

• Implement aggressive dietary modifications (cholesterol-lowering diet)
• Evaluate for secondary causes of hyperlipidemia (hypothyroidism, nephrotic syndrome, medications)
• Assess baseline LDL-C and cardiovascular risk status

Step 2: Initial Non-Statin Therapy - Ezetimibe

Begin with ezetimibe 10 mg daily as the preferred initial agent based on 2022 ACC guidelines 1. This recommendation is supported by:

• Demonstrated cardiovascular outcomes benefit in the IMPROVE-IT trial when combined with statins
• Excellent safety profile with minimal side effects
• Oral administration (no injections required)
• Well-tolerated in statin-intolerant patients 2, 3

Step 3: Add Bempedoic Acid if LDL-C Goals Not Met

If ezetimibe alone fails to achieve target LDL-C reduction (typically <70 mg/dL for ASCVD patients or <100 mg/dL for primary prevention):

Add bempedoic acid 180 mg daily, which provides an additional ~17% LDL-C reduction 1. Key considerations:

• Works upstream of statins in cholesterol synthesis pathway
• Does not cause muscle symptoms (not activated in muscle tissue)
• Oral medication, once daily
• Caution: Use carefully in patients with history of gout or tendon rupture 1
• No cardiovascular outcomes data yet available 1

Step 4: Consider Bile Acid Sequestrants

If additional LDL-C lowering needed or as alternative to bempedoic acid:

Bile acid sequestrants (colesevelam preferred) can be added 1, 3:

• Reduces LDL-C by 15-25%
• Proven cardiovascular benefit in older trials
• Major limitation: Gastrointestinal side effects (bloating, constipation) limit tolerability
• Drug-drug interactions require careful timing with other medications

Step 5: Inclisiran as Alternative PCSK9 Strategy

If the patient specifically cannot tolerate PCSK9 monoclonal antibodies (injection site reactions, adherence issues) but inclisiran might be acceptable:

Inclisiran 284 mg subcutaneously can be considered 1:

• Administered only twice yearly (after initial dose and 3-month dose)
• Reduces LDL-C by ~50%
• May be better tolerated than monoclonal antibodies
• Important caveat: No cardiovascular outcomes data yet (trials ongoing until 2026-2027) 1
• Should replace, not add to, PCSK9 monoclonal antibodies

Step 6: Specialized Therapies for Severe Cases

For patients with baseline LDL-C ≥190 mg/dL or familial hypercholesterolemia who remain uncontrolled:

Refer to lipid specialist for consideration of 1:

• LDL apheresis: For persistent LDL-C >200 mg/dL despite maximal medical therapy
• Lomitapide: For homozygous familial hypercholesterolemia (FDA-approved but significant hepatotoxicity risk)
• Evinacumab: ANGPTL3 inhibitor for homozygous FH (LDL receptor-independent mechanism) 4

Realistic LDL-C Reduction Expectations

When combining non-statin therapies without statins or PCSK9 inhibitors:

• Ezetimibe alone: 15-20% reduction
• Ezetimibe + bempedoic acid: 30-35% combined reduction
• Ezetimibe + bile acid sequestrant: 30-40% combined reduction
• Triple therapy (ezetimibe + bempedoic acid + bile acid sequestrant): 40-50% reduction possible but limited by tolerability

Critical Clinical Pitfalls

1. Don't assume true statin intolerance without rechallenge: The 2022 ACC guidelines emphasize trying at least 3 different statins at various doses/schedules before declaring complete intolerance 1. Consider alternate-day or twice-weekly dosing regimens.

2. Verify the reason PCSK9 inhibitors cannot be used: If cost or injection aversion is the issue rather than true adverse effects, inclisiran's twice-yearly dosing may be acceptable 1.

3. Monitor for bempedoic acid-specific risks: Check baseline uric acid and tendon health history before initiating 1.

4. Set realistic expectations: Without statins or PCSK9 inhibitors, achieving very aggressive LDL-C targets (<55 mg/dL for very high-risk patients) may be impossible with currently available therapies 1.

5. Don't delay referral to lipid specialist: Patients with severe hypercholesterolemia (LDL-C >190 mg/dL) or suspected familial hypercholesterolemia should be referred early, not after exhausting all options 1.

Target LDL-C Goals

Based on cardiovascular risk stratification 1, 5:

• Very high-risk ASCVD: <55 mg/dL and ≥50% reduction from baseline
• High-risk ASCVD: <70 mg/dL and ≥50% reduction from baseline
• Primary prevention with risk factors: <100 mg/dL
• Severe hypercholesterolemia (≥190 mg/dL): <70 mg/dL minimum

The combination of ezetimibe plus bempedoic acid represents the most evidence-based, practical approach for patients who genuinely cannot use statins or PCSK9 inhibitors, though cardiovascular outcomes data for this specific combination remains limited 2, 4.